Deprenyl Research Ltd. said it has received Canadiangovernment approval to distribute Alzene to Alzheimer'sdisease patients upon doctor's request.
Doctors must receive authorization from regulatory authoritieson a case-by-case basis, according to James Doherty, presidentof the Toronto company (NASDAQ:DEPLF).
Alzene is a composition of fatty acids believed to improve theneuronal cell membrane fluidity associated with the disease.Deprenyl licensed rights to the compound from Ivax Corp.(AMEX:IVX) last July. According to Ivax, preliminary data fromstudies conducted in Israel indicated that Alzene improves thecognitive functions of Alzheimer's patients by 70 percent.
Deprenyl has started Phase II Canadian trials of the drug'seffect on memory in normal adults, and plans a second trial inAlzheimer's patients. In February, Ivax's Baker CumminsPharmaceuticals Inc. subsidiary started started U.S. Phase IItrials in Alzheimer's patients. Deprenyl stock was unchanged at$14.38-- HG
(c) 1997 American Health Consultants. All rights reserved.